Literature DB >> 20145095

The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells.

Mohamed Hafez1, Kelly Hayes, Marie Goldrick, Richard K Grencis, Ian S Roberts.   

Abstract

Escherichia coli strain Nissle 1917, which has been widely used as a probiotic for the treatment of inflammatory bowel disorders, expresses a K5 capsule, the expression of which is often associated with extraintestinal and urinary tract isolates of E. coli. Previously, it had been shown that the expression of a K5 capsule by Nissle 1917 was important in mediating interactions with epithelial cells and the extent of chemokine expression. In this paper, we show that infection with Nissle 1917 induces expression of Toll-like receptor 4 (TLR4) and TLR5 in Caco-2 cells and that maximal induction of TLR5 required the K5 capsule. In addition, purified K5 polysaccharide was capable of inducing expression of TLR5 and mCD14 and potentiated the activity of both TLR4 and TLR5 agonists to increase the proinflammatory response. Infection with Nissle 1917 also increased the expression of the adaptor molecules MyD88 and TRIF, which was K5 capsule dependent. By Western blot analysis, it was possible to show that induction of interleukin-8 by Nissle 1917 was predominantly through the mitogen-activated protein (MAP) kinase pathway and that expression of the K5 capsule was important for activation of the MAP kinase pathway. This paper provides new information on the function of the K5 capsule in mediating interactions between Nissle 1917 and epithelial cells and the mechanisms that underlie the probiotic properties of Nissle 1917.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145095      PMCID: PMC2863526          DOI: 10.1128/IAI.01406-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

Review 1.  Mitogen-activated protein kinases: specific messages from ubiquitous messengers.

Authors:  H J Schaeffer; M J Weber
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria.

Authors:  Martin L Cross; Anja Ganner; Diaa Teilab; Linley M Fray
Journal:  FEMS Immunol Med Microbiol       Date:  2004-10-01

3.  Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid.

Authors:  Ling Zheng; Terrence E Riehl; William F Stenson
Journal:  Gastroenterology       Date:  2009-09-02       Impact factor: 22.682

4.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

Review 5.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways.

Authors:  A J Whitmarsh; R J Davis
Journal:  J Mol Med (Berl)       Date:  1996-10       Impact factor: 4.599

6.  Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants.

Authors:  R Lodinová-Zádniková; U Sonnenborn
Journal:  Biol Neonate       Date:  1997

7.  Capsular polysaccharide types 5 and 8 of Staphylococcus aureus bind specifically to human epithelial (KB) cells, endothelial cells, and monocytes and induce release of cytokines.

Authors:  M Soell; M Diab; G Haan-Archipoff; A Beretz; C Herbelin; B Poutrel; J P Klein
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

8.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)].

Authors:  M Möllenbrink; E Bruckschen
Journal:  Med Klin (Munich)       Date:  1994-11-15

10.  In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain.

Authors:  Jean-Christophe Bambou; Antoine Giraud; Sandrine Menard; Bernadette Begue; Sabine Rakotobe; Martine Heyman; François Taddei; Nadine Cerf-Bensussan; Valérie Gaboriau-Routhiau
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

View more
  19 in total

Review 1.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

Review 2.  Probiotics: properties, examples, and specific applications.

Authors:  Judith Behnsen; Elisa Deriu; Martina Sassone-Corsi; Manuela Raffatellu
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

3.  Toward an Alternative Therapeutic Approach for Skin Infections: Antagonistic Activity of Lactobacilli Against Antibiotic-Resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Mohamed M Hafez; Ibrahim A Maghrabi; Noha M Zaki
Journal:  Probiotics Antimicrob Proteins       Date:  2013-09       Impact factor: 4.609

4.  Upregulation of Intestinal Mucin Expression by the Probiotic Bacterium E. coli Nissle 1917.

Authors:  Mohamed M Hafez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

5.  TcpC protein from E. coli Nissle improves epithelial barrier function involving PKCζ and ERK1/2 signaling in HT-29/B6 cells.

Authors:  N A Hering; J F Richter; A Fromm; A Wieser; S Hartmann; D Günzel; R Bücker; M Fromm; J D Schulzke; H Troeger
Journal:  Mucosal Immunol       Date:  2013-07-31       Impact factor: 7.313

6.  Adaptive Strategies of the Candidate Probiotic E. coli Nissle in the Mammalian Gut.

Authors:  Nathan Crook; Aura Ferreiro; Andrew J Gasparrini; Mitchell W Pesesky; Molly K Gibson; Bin Wang; Xiaoqing Sun; Zevin Condiotte; Stephen Dobrowolski; Daniel Peterson; Gautam Dantas
Journal:  Cell Host Microbe       Date:  2019-03-26       Impact factor: 21.023

7.  Identification and characterisation of an iron-responsive candidate probiotic.

Authors:  Jennifer R Bailey; Christopher S J Probert; Tristan A Cogan
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

8.  Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles.

Authors:  Joseph A Rosenthal; Chung-Jr Huang; Anne M Doody; Tiffany Leung; Kaho Mineta; Danielle D Feng; Elizabeth C Wayne; Nozomi Nishimura; Cynthia Leifer; Matthew P DeLisa; Susana Mendez; David Putnam
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

9.  Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health.

Authors:  Jonathan Nzakizwanayo; Sandeep Kumar; Lesley A Ogilvie; Bhavik A Patel; Cinzia Dedi; Wendy M Macfarlane; Brian V Jones
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

10.  Activation of Immune and Defense Responses in the Intestinal Mucosa by Outer Membrane Vesicles of Commensal and Probiotic Escherichia coli Strains.

Authors:  María José Fábrega; Laura Aguilera; Rosa Giménez; Encarna Varela; María Alexandra Cañas; María Antolín; Josefa Badía; Laura Baldomà
Journal:  Front Microbiol       Date:  2016-05-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.